RAP 0.00% 20.5¢ raptor resources limited

Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic, page-58

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
  1. 27,363 Posts.
    lightbulb Created with Sketch. 1776
    3 products in acute respiratory diagnosis, chronic respiratory management and OSA which all have massive revenue potential, this will be doubtful. IMO, the global revenue for just SleepCheck can bring in $4M.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.